SLC5A2 and diabetes mellitus: In these large trials, treatment with SGLT2 inhibitors in combination with optimal medical therapy (ACEI/ARNI, β-blockers, and MRAs) in patients with symptomatic chronic HF is associated with a reduction in the risk of hospitalization for HF and cardiovascular mortality, regardless of the presence of DM and across all LVEF.